Date of upload:
Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Michael Peter Ellis, James Jeffery Peoples, James Joseph Meuer, Johanne Dodon, John Lawrence Griffin, John Suzuki, Joseph Michael Foty, Judy Weber, Julia Grace McCammon, Karen Brynes Allen, Kathryn Regina Sweas, Lezley Jo-Anne Wright, Lisa A. Knoll, Madeline E. Michaels, Margaret Kweya Wahl, Mark E. Stutheit, Michelle Barnard, Muriel Mae Ranger, Paromvong Sinbandhit
With the increasing popularity of herbomineral preparations in healthcare, a new proprietary herbomineral formulation was formulated with ashwagandha root extract and minerals viz. zinc, magnesium, and selenium. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect®) on the herbomineral test formulation using mice splenocytes. The test formulation was divided into two parts. One part was the control without the Biofield Treatment. The other part was labelled the Biofield Treated sample, which received the Biofield Energy Healing Treatment remotely from twenty renowned Biofield Energy Healers. The splenocyte cells were exposed with the test formulation at ranges of 0.00001053 to 10.53 µg/mL for cell viability by MTT assay, with cell viability ranging from 77.50% to 176.52%. TNF-α was significantly inhibited by 15.88%, 15.28%, 12.30%, 12.60%, and 22.72% at 0.00001053, 0.001053, 0.1053, 1.053, and 10.53 µg/mL, respectively in the Biofield Treated test formulation compared to the vehicle control (VC). TNF-α was significantly reduced by 2.33% and 8.35% at 1.053 and 10.53 µg/mL, respectively compared to the untreated test formulation. IL-1β was significantly reduced by 30.81%, 27.36%, 23.92%, 18.40%, 11.27%, and 21.16% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, and 1.053 µg/mL, respectively in the Biofield Treated test formulation compared to the VC. IL-1β was significantly reduced by 48.63% (p≤0.001) and 15.28% at 0.00001053 and 0.0001053 µg/mL, respectively in the Biofield Treated test formulation compared to the untreated test formulation. MIP-1α expression was inhibited by the Biofield Treated test formulation and showed immunosuppressive activity at 0.01053, 0.1053, 1.053, and 10.53 µg/mL by 22.33%, 16.25%, 15.58%, and 21.83%, respectively compared to the VC. The Biofield Treated test formulation significantly reduced the MIP-1α expression by 13.27% and 15.67% (p<0.05) at 0.01053 and 10.53 µg/mL, respectively compared to the untreated test formulation. The results showed the expression of IFN-γ was significantly reduced by 33.45%, 25.38%, 37.15%, 27.74%, 32.44%, 23.03%, and 44.21% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053, and 10.53 µg/mL, respectively in the Biofield Treated test formulation compared to the VC. Further, the IFN-γ level was significantly decreased by 19.02% at 10.53 µg/mL in the Biofield Treated test formulation compared to the untreated test formulation. Overall, the results demonstrate that The Trivedi Effect® Biofield Energy Healing (TEBEH) significantly enhanced the anti-inflammatory and immunomodulatory properties of the treated formulation, and may also be useful in organ transplants, anti-aging, and stress management by improving overall health and quality of life.